CGMP/Finished Pharmaceuticals/Adulterated
Similar Posts
FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma
On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem celFoshan Yiying Hygiene Products Co., Ltd. – 715548 – 10/10/2025
CGMP/Finished Pharmaceuticals/AdulteratedBiomarker Qualification Program
The Drug Development Tools (DDT) Research Grant Cycle for Fiscal Years (FY) 2024 is now open.Fuentes Farms, LLC Recalls Product Because of Possible Health Risk
Fuentes Farms of McAllen, Texas is recalling 71 Boxes of Fresh Cucumbers, because it has the potential to be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. HealthyDivision of Oncology 2 (DO2)
The Division of Oncology 2 (DO2) regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs) and Biologic Licensing Applications (BLAs) for the following therapeutic areas: gastrointestinal, lung, and head and neck cancers; neuro-oncology, rare cancers, pediatricUpdate on Alert: Defibrillation Lead Issue from Boston Scientific
This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program.